Floatz logo

Ntx-1088

Tumor, Solid

Nectin Therapeutics Ltdmonoclonal_antibodyPhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

927 Active assets in the Tumor, Solid cohort.

Asset / SponsorPhaseRating
PANITUMUMAB
Astellas Pharma Inc
Phase 2BBB
GRANULOCYTE COLONY-STIMULATING FACTOR LENOGRASTIM
Sanofi
Phase 4BB
Inno-206
The First Affiliated Hospital of Soochow University
Phase 2/3BB
DINITROGEN MONOXIDE
Medical College of Wisconsin
Phase 4BB
Glycopyrrolate
Medical College of Wisconsin
Phase 4BB

View all 50 →

Same molecule, other indications

Ntx-1088 is also rated in:

Locally Advanced Solid TumorDormant
CC
Indicative ·
41 / 100
View asset →
metastatic malignant neoplasmDormant
C
Indicative ·
39 / 100
View asset →
cancerDormant
C
Indicative ·
37 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →